Pembrolizumab has inadequate effectiveness in earlier therapeutics of glioblastoma, exclusive of those cases with definitive mismatch repair defects.70, 71, 72, 73Nivolumab, when mixed with bevacizumab and chemoradiotherapy in recently diagnosed glioblastoma individuals along with MGMT promoter unmethylation, was unsuccessful.74 This evidence concerns the gene MGMT and glioblastoma.